CrossrefInfokarte
Telisotuzumab vedotin: The first-in-class c-Met-targeted antibody-drug conjugate granted FDA accelerated approval for treatment of non-squamous non-small cell lung cancer (NSCLC)
Drug Discoveries & Therapeutics · 2025-08-31 · 19 (4) · 275-276
DOI: 10.5582/ddt.2025.01058 ↗Abstract
Kein Abstract verfügbar.
EUVIMED